AGT-182, comprised of a fusion of iduronate 2-sulfatase (IDS) to the C-termini of the anti-INSR HCs (Boado et al., 2014), is under phase I clinical testing (NCT02262338) for the treatment of mucopolysaccharidosis II (MPS II; Hunter Syndrome). The gene discussed is AGT; the disease is mucopolysaccharidosis type 2.